BCL2 and Miyoshi myopathy: The BCL-2 inhibitor venetoclax is under investigation for relapsed/refractory MM, specifically to assess effectiveness in patients carrying t(11;14) following the phase 3 BELLINI trial (NCT02755597) of venetoclax plus Vd versus placebo plus Vd, that demonstrated an increased risk of mortality in the overall population but a more favorable risk–benefit profile in patients with t(11;14) or BCL-2-high gene expression [48].